Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Cisplatin
  • Drug Resistance, Neoplasm
  • Neoplasms, Germ Cell and Embryonal
  • Testicular Neoplasms

abstract

  • BRAF mutations are rare in American patients with GCT, including those with cisplatin resistance. However, other potentially targetable mutations occur in more than 25% of cisplatin-resistant patients. FGFR3, AKT1, and PIK3CA mutations are all reported for the first time in GCT. Whereas FGFR3 mutations occurred with equal frequency in both sensitive and resistant GCTs, mutations in AKT1 and PIK3CA were observed exclusively in cisplatin-resistant tumors.

publication date

  • July 15, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-13-2868

PubMed ID

  • 24812411

Additional Document Info

start page

  • 3712

end page

  • 20

volume

  • 20

number

  • 14